Your browser doesn't support javascript.
loading
mRNA vaccine design for Epstein-Barr virus: an immunoinformatic approach.
Oladipo, Elijah Kolawole; Akinleye, Temitope Michael; Adeyemo, Stephen Feranmi; Akinboade, Modinat Wuraola; Siyanbola, Kehinde Favour; Adetunji, Victoria Ademide; Arowosegbe, Olukayode Abimbola; Olatunji, Victoria Kehinde; Adaramola, Esther Oluwadarasimi; Afolabi, Hezekiah Omotayo; Ajani, Christianah Damilola; Siyanbola, Taiwo Pleasure; Folakanmi, Elizabeth Oluwatoyin; Irewolede, Boluwatife Ayobami; Okesanya, Olalekan John; Ajani, Olumide Faith; Ariyo, Olumuyiwa Elijah; Jimah, Esther Moradeyo; Iwalokun, Bamidele Abiodun; Kolawole, Olatunji Matthew; Oloke, Julius Kola; Onyeaka, Helen.
Afiliación
  • Oladipo EK; Laboratory of Molecular Biology, Immunology and Bioinformatics, Department of Microbiology, Adeleke University, Ede, Osun State Nigeria.
  • Akinleye TM; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Adeyemo SF; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Akinboade MW; Department of Anatomy and Advanced Research Center for Tumor Immunology, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan, 47392 Republic of Korea.
  • Siyanbola KF; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Adetunji VA; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Arowosegbe OA; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Olatunji VK; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Adaramola EO; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Afolabi HO; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Ajani CD; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Siyanbola TP; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Folakanmi EO; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Irewolede BA; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Okesanya OJ; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Ajani OF; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Ariyo OE; Faculty of Medicine, Department of Public Health and Maritime Transport, Laboratory of Hygiene and Epidemiology, University of Thessaly, Papakyriazi 22, Larissa, 41222 Greece.
  • Jimah EM; African Centre for Disease Control and Prevention (African CDC), Addis Ababa, Ethiopia.
  • Iwalokun BA; Department of Medicine, Infectious Diseases and Tropical Medicine Unit, Federal Teaching Hospital, Ido-Ekiti, Ekiti State Nigeria.
  • Kolawole OM; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.
  • Oloke JK; Molecular Biology and Biotechnology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
  • Onyeaka H; Department of Microbiology, University of Ilorin, Ilorin, 234031 Nigeria.
In Silico Pharmacol ; 12(2): 68, 2024.
Article en En | MEDLINE | ID: mdl-39070665
ABSTRACT
Epstein-Barr Virus (EBV), structurally similar to other herpes viruses, possess significant global health challenges as it causes infectious mononucleosis and is also associated with various cancers. Due to this widespread impact, an effective messenger RNA (mRNA) vaccine is paramount to help curb its spread, further underscoring the need for its development. This study, following an immunoinformatic approach, aimed to design a comprehensive mRNA vaccine against the EBV by selecting antigenic proteins, predicting Linear B-cell epitopes, cytotoxic T-cell lymphocyte (CTL) and helper T-cell lymphocyte (HTL) epitopes, and assessing vaccine characteristics. Seventy-nine EBV isolates from diverse geographical regions were examined. Additionally, the vaccine construct's physicochemical properties, transmembrane domains, solubility, and secondary structures were analysed. Molecular docking was conducted with Toll-Like Receptor 5 (TLR-5). Population coverage was assessed for selected major histocompatibility complex (MHC) alleles, and immune response was simulated. The result of this study highlighted a vaccine construct with high antigenicity, non-toxicity, and non-allergenicity and possessed favourable physicochemical properties. The vaccine's 3D structure is native-like and strongly binds with TLR-5, indicating a solid affinity with TLR-5. The selected MHC alleles provided broad universal population coverage of 89.1%, and the immune simulations suggested a robust and wide-ranging immunogenic response, activating critical immune cells, antibodies, and cytokines. These findings provide a solid foundation for further development and testing of the EBV candidate vaccine, offering potential solutions for combating EBV infections.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: In Silico Pharmacol Año: 2024 Tipo del documento: Article Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: In Silico Pharmacol Año: 2024 Tipo del documento: Article Pais de publicación: Alemania